Publicacións en colaboración con investigadores/as de Charité (22)

2024

  1. Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry

    European Journal of Heart Failure

2023

  1. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry

    European journal of preventive cardiology, Vol. 30, Núm. 13, pp. 1346-1358

  2. Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1049-1060

  3. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC-HFA Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1061-1071

  4. Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery

    European Journal of Heart Failure, Vol. 25, Núm. 12, pp. 2316-2330

2021

  1. Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling

    Circulation, Vol. 144, Núm. 25, pp. 2021-2034

  2. Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department

    ESC Heart Failure, Vol. 8, Núm. 6, pp. 4409-4424

  3. Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry

    ESC Heart Failure, Vol. 8, Núm. 6, pp. 4955-4967

2020

  1. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1424-1437

  2. Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry

    ESC Heart Failure, Vol. 7, Núm. 5, pp. 2098-2112

  3. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

    Journal of cardiovascular pharmacology, Vol. 76, Núm. 1, pp. 4-22

  4. Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use

    Cardiac Failure Review, Vol. 6

  5. Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure

    European Journal of Heart Failure

  6. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 1, pp. 92-102

  7. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1378-1389

2019

  1. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus

    International Journal of Cardiology, Vol. 297, pp. 83-90

  2. Effects of serelaxin in patients with acute heart failure

    New England Journal of Medicine, Vol. 381, Núm. 8, pp. 716-726

  3. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1383-1397

2018

  1. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: A report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry

    European Heart Journal, Vol. 39, Núm. 48, pp. 4277-4284

  2. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 20, Núm. 1, pp. 16-37